Yvonne Greenstreet
Chief Executive Officer at Alnylam Pharmaceuticals Inc.
Sits on 1 board. Last updated September 28, 2026
Time on boards
- Boards served
- 1
- Current seats
- 1
- Board service
- 4 years
- Director since
- 2023
4 years of board service in total across 1 board, counting each seat separately. Longest: Alnylam Pharmaceuticals Inc., 3 years.
Alnylam Pharmaceuticals Inc.
Director · Chief Executive Officer
Chief executive roles
Alnylam Pharmaceuticals Inc.
· Chief Executive Officer
Dates unknown
Insider trades
All notable trades →From SEC Forms 4 and 5. Open-market purchases and sales are highlighted; grants, option exercises and shares withheld for tax are routine.
| Date | Company | Transaction | Shares | Price | Value |
|---|---|---|---|---|---|
| Aug 18, 2025 | Alnylam Pharmaceuticals Inc. | Open-market sale | −194 | $447.98 | $86,908 |
| Aug 18, 2025 | Alnylam Pharmaceuticals Inc. | Open-market sale | −450 | $449.92 | $202,464 |
| Aug 18, 2025 | Alnylam Pharmaceuticals Inc. | Open-market sale | −195 | $450.92 | $87,929 |
| Aug 18, 2025 | Alnylam Pharmaceuticals Inc. | Open-market sale | −514 | $451.99 | $232,323 |
| Aug 18, 2025 | Alnylam Pharmaceuticals Inc. | Open-market sale | −1,646 | $452.96 | $745,572 |
| Aug 18, 2025 | Alnylam Pharmaceuticals Inc. | Open-market sale | −2,716 | $454.04 | $1,233,173 |
| Aug 18, 2025 | Alnylam Pharmaceuticals Inc. | Open-market sale | −1,204 | $454.84 | $547,627 |
| Aug 18, 2025 | Alnylam Pharmaceuticals Inc. | Open-market sale | −60 | $455.82 | $27,349 |
| Aug 15, 2025 | Alnylam Pharmaceuticals Inc. | Grant or award | +14,252 | — | — |
| Jun 2, 2025 | Alnylam Pharmaceuticals Inc. | Option exercise | +12,080 | $119.13 | $1,439,090 |
| Jun 2, 2025 | Alnylam Pharmaceuticals Inc. | Option exercise | +7,217 | $118.05 | $851,967 |
| Jun 2, 2025 | Alnylam Pharmaceuticals Inc. | Open-market sale | −19,297 | $306.00 | $5,904,882 |
| May 30, 2025 | Alnylam Pharmaceuticals Inc. | Option exercise | +12,081 | $119.13 | $1,439,210 |
| May 30, 2025 | Alnylam Pharmaceuticals Inc. | Option exercise | +19,559 | $118.05 | $2,308,940 |
| May 30, 2025 | Alnylam Pharmaceuticals Inc. | Open-market sale | −25,469 | $304.00 | $7,742,576 |
Reviews (0)
Sign in to write a review.
No reviews yet. Be the first to write one.